HALIX B.V.

At HALIX, we are dedicated to empowering biotech companies create life-saving therapeutics and deliver them to those in need, enabled by three key strengths:. We are a fast growing, contract development and manufacturing organization (CDMO) focused on mammalian expression systems for the production of viral vectors, viral vector vaccines and recombinant proteins. HALIX was established as an 100% subsidiary of HAL Allergy Holding B. At HALIX, we understand the importance of such a challenge and are dedicated to forming true partnerships with our customers. In HALIX we found the ideal partner; experience in transient transfection, modern facilities, strong leadership and a laser focus on delivery to bring NVG-111 from contract signature to vials of clinical drug in less than seven months.“. HALIX offered a full service to match our needs and provided us with the flexibility and collaboration that was necessary to deliver T-Guard® to clinical trials. HALIX’s attention to detail and close, transparent communication enabled us to meet our deadlines, successfully overcome challenges, and ensure the success of the project.”. HALIX Appoints Richard van Rijnsoever as Vice President of Business Development and Project Management.